Bionano Genomics
BNGO
48 hedge funds and large institutions have $2.48M invested in Bionano Genomics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 14 closing their positions.
342% more call options, than puts
Call options by funds: $106K | Put options by funds: $24K
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
3.18% less ownership
Funds ownership: 9.56% → 6.38% (-3.2%)
9% less funds holding
Funds holding: 53 → 48 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
45% less capital invested
Capital invested by funds: $4.48M → $2.48M (-$2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$129K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$74K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.2K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$52.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.14M |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$106K |
| 3 |
Jane Street
New York
|
-$32.9K |
| 4 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$27.3K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$21K |
BNGO Hedge Fund Activity: Q3 2024 in Review
48 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q3 2024, worth a combined $2.48M — down 45% from $4.48M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of BNGO and 9 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Geode Capital Management, adding an estimated $147K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.14M sold.
- 48 institutional investors held Bionano Genomics (BNGO) as of Q3 2024, down from 53 in Q2 2024.
- Funds reported $2.48M of Bionano Genomics stock for Q3 2024, down 45% quarter-over-quarter.
- 9 funds opened new Bionano Genomics positions in Q3 2024 and 14 closed out, a net change of -5 holders.
- The largest Bionano Genomics buyer in Q3 2024 was Geode Capital Management, an estimated $147K added.
- The largest Bionano Genomics seller in Q3 2024 was Armistice Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q3 2024.